Overview

Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea

Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy of Octreotide LAR in preventing chemotherapy-induced diarrhea (with regimens that contain 5 fluorouracil, irinotecan and capecitabine)in patients with colorectal cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Octreotide